Global Homatropine Hydrobromide Market Size By Type (Injection, Tablet), By Application (Mydriasis, Other), By Region, And Segment Forecasts, 2023 to 2032

The Global Homatropine Hydrobromide Market was valued at USD 412 million in 2023 and is projected to surpass USD 615 million by 2031, growing at a CAGR of 5.2% during the forecast period from 2023 to 2031. Homatropine hydrobromide is an anticholinergic medication used in ophthalmology to dilate the pupil and treat uveitis. Its increasing demand stems from the rising prevalence of eye disorders, expanding aging population, and growing awareness about ophthalmic health. The pharmaceutical sector's innovation and the broader use of homatropine in preoperative and diagnostic procedures are fueling the global market growth.

Drivers:

Rising Prevalence of Ophthalmic Disorders:

Age-related macular degeneration, glaucoma, and uveitis are becoming increasingly common, particularly in older populations. As the global geriatric population rises, so does the demand for ophthalmic medications like homatropine hydrobromide.

Expanding Geriatric Population:

With aging being a significant risk factor for most eye-related conditions, the growing elderly demographic worldwide is contributing to the rising demand for homatropine-based treatments.

Growth in Eye Care Awareness:

Governments and NGOs are promoting regular eye checkups, leading to higher diagnosis rates of ocular conditions that require pharmacologic pupil dilation, subsequently increasing product usage.

Restraints:

Stringent Regulatory Approvals:

The approval process for ophthalmic drugs is often rigorous, involving extensive clinical trials. This increases the time and cost involved in bringing new formulations to market.

Availability of Alternatives:

Other mydriatic agents like atropine and tropicamide offer similar effects, which can limit homatropine hydrobromide's market penetration in certain therapeutic areas.

Opportunity:

Emerging Markets Expansion:

Rapid urbanization and improvements in healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East are providing lucrative opportunities for market players, particularly in countries with large aging populations.

Product Innovation and Combination Therapies:

New formulations combining homatropine with anti-inflammatory or antibiotic agents are being developed, offering enhanced therapeutic benefits and opening new market segments.

Market by System Type Insights:

Based on formulation type, the ophthalmic solution segment held the largest share in 2023. This dominance is driven by its widespread use in outpatient eye care for diagnostic procedures and inflammation management. Meanwhile, the injectable segment is anticipated to register moderate growth due to its limited but specialized applications in surgical settings.

Market by End-use Insights:

In terms of end-use, hospitals and specialty clinics accounted for the largest share of the market in 2023. This is due to the frequency of eye exams, diagnostic procedures, and surgeries performed in such settings. The retail pharmacy segment is also growing steadily, supported by rising over-the-counter availability in regulated dosages for pre-surgical use.

Market by Regional Insights:

North America dominated the global market in 2023, attributed to a high prevalence of eye diseases, advanced healthcare infrastructure, and strong pharmaceutical R&D activity. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period due to increasing healthcare access, rising aging population, and greater adoption of modern eye care practices in countries like India and China.

Competitive Scenario:

Key players in the Global Homatropine Hydrobromide Market include Akorn Pharmaceuticals, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Allergan plc (an AbbVie company), and Sigma-Aldrich (a Merck KGaA company). These companies focus on R&D innovation, strategic mergers, and global distribution expansions. Recent developments include:

2023: Bausch Health expanded its ophthalmic production facility to scale up the manufacturing of homatropine-based formulations.

2024: Akorn Pharmaceuticals introduced a preservative-free version of homatropine ophthalmic solution aimed at sensitive eye care markets.

2025: Allergan announced a partnership with an AI-driven diagnostics firm to enhance drug targeting in ophthalmology.

Scope of Work – Global Homatropine Hydrobromide Market

Key Market Developments:

Akorn Pharmaceuticals (2024): Launched preservative-free eye drops for safer and more comfortable patient use.

Santen Pharmaceutical (2023): Received regulatory approval for its homatropine-based combination therapy in Japan.

Allergan (2025): Partnered with AI-based imaging companies to target homatropine prescriptions more effectively.

FAQs:

1. What is the current market size of the Global Homatropine Hydrobromide Market?

The market was valued at USD 412 million in 2023.

2. What is the major growth driver of the Global Homatropine Hydrobromide Market?

The major growth driver is the rising prevalence of ophthalmic disorders and an expanding aging population.

3. Which is the largest region during the forecast period in the Global Homatropine Hydrobromide Market?

North America held the largest market share in 2023.

4. Which segment accounted for the largest market share in Global Homatropine Hydrobromide Market?

The ophthalmic solution segment accounted for the largest share based on formulation type.

5. Who are the key market players in the Global Homatropine Hydrobromide Market?

Key players include Akorn Pharmaceuticals, Bausch Health, Allergan, Santen Pharmaceutical, and Sigma-Aldrich.